GPX4 and B-cell non-Hodgkin lymphoma: As anticipated, overexpression of GPX4 led to higher GPX4 levels following HDL NP treatment compared with controls (Fig. S6, C) and protected B cell lymphoma cells from HDL NP–induced cell death compared with controls (Fig. S6, D).